https://www.pharmaradar360.com/article/high-costs-taxes-keep-nigeria-dependent-on-imported-drug-inputs-psn-de7b24572476461cPharmaRadar360en2026-09-27T15:33:40.000ZHigh Costs,Taxes Keep Nigeria Dependent On Imported Drug Inputs—PSNhttps://www.pharmaradar360.com/article/form-144-legend-biotech-corp-for-27-september-by-investing-com-325ce041d79d35b0PharmaRadar360en2026-09-27T13:48:09.000ZForm 144 Legend Biotech Corp For: 27 September By Investing.comhttps://www.pharmaradar360.com/article/3-indian-growth-stocks-with-revenue-growth-up-to-27-43fee28c579d870fPharmaRadar360en2026-09-27T13:38:03.000Z3 Indian Growth Stocks With Revenue Growth Up To 27%https://www.pharmaradar360.com/article/fake-anti-rabies-vaccines-case-fir-lodged-against-two-kanpur-pharmaceutical-agen-3d8f5c7c69891897PharmaRadar360en2026-09-27T12:56:33.000ZFake Anti-Rabies Vaccines Case: FIR Lodged Against Two Kanpur Pharmaceutical Agencieshttps://www.pharmaradar360.com/article/state-street-spdr-s-p-biotech-etf-xbi-stock-price-news-quote-history-d4dae5114aa6fc80PharmaRadar360en2026-09-27T12:55:33.000ZState Street SPDR S&P Biotech ETF (XBI) Stock Price, News, Quote & Historyhttps://www.pharmaradar360.com/article/innovation-is-driving-a-new-bull-market-in-biotech-16-ways-to-play-it-from-our-r-fe116bb5058c4328PharmaRadar360en2026-09-27T12:46:00.000ZInnovation Is Driving a New Bull Market in Biotech. 16 Ways to Play It, From Our Roundtable Experts.https://www.pharmaradar360.com/article/china-s-advances-in-pharma-create-new-opportunities-for-pakistan-f139216a76bfd03ePharmaRadar360en2026-09-27T12:45:00.000ZChina’s advances in pharma create new opportunities for Pakistanhttps://www.pharmaradar360.com/article/fda-approves-new-parkinson-s-drug-that-targets-dopamine-receptors-all-about-tava-783438ee9fbeb0ffPharmaRadar360en2026-09-27T12:30:00.000ZFDA Approves New Parkinson’s Drug That Targets Dopamine Receptors: All About Tavapadonhttps://www.pharmaradar360.com/article/two-chinese-ipos-open-for-subscription-monday-guizhou-s-southern-dairy-at-14-21-99d23c8c332cc0f6PharmaRadar360en2026-09-27T12:25:00.000ZTwo Chinese IPOs Open for Subscription Monday: Guizhou's Southern Dairy at 14.21 Yuan, Lianya Pharmaceutical Seen as High Allotment-Rate Playhttps://www.pharmaradar360.com/article/iberdomide-doubles-mrd-negative-cr-rate-in-phase-3-excaliber-rrmm-trial-ec3c4892a0321716PharmaRadar360en2026-09-27T12:05:26.000ZIberdomide Doubles MRD-Negative CR Rate in Phase 3 EXCALIBER-RRMM Trialhttps://www.pharmaradar360.com/article/mount-kenya-university-to-unveil-new-pharmacy-courses-fa16b2c3a84651c3PharmaRadar360en2026-09-27T12:03:29.000ZMount Kenya University to unveil new pharmacy courseshttps://www.pharmaradar360.com/article/form-4-teva-pharmaceutical-industries-ltd-for-27-september-by-investing-com-42d0210e01173842PharmaRadar360en2026-09-27T11:32:00.000ZForm 4 TEVA PHARMACEUTICAL INDUSTRIES LTD For: 27 September By Investing.comhttps://www.pharmaradar360.com/article/tributes-paid-after-death-of-powys-pharmaceutical-pioneer-sir-roger-jones-a317651e7abf0b33PharmaRadar360en2026-09-27T11:00:00.000ZTributes paid after death of Powys pharmaceutical pioneer Sir Roger Joneshttps://www.pharmaradar360.com/article/the-gray-zone-between-wellness-and-medical-practice-as-experts-urge-strict-overs-d610109d330fb461PharmaRadar360en2026-09-27T10:55:03.000ZThe gray zone between wellness and medical practice as experts urge strict oversight in Cyprushttps://www.pharmaradar360.com/article/uzbekistan-eyes-investment-in-afghanistan-s-pharmaceutical-sector-3b860121a6a54363PharmaRadar360en2026-09-27T10:52:38.000ZUzbekistan Eyes Investment in Afghanistan’s Pharmaceutical Sectorhttps://www.pharmaradar360.com/article/vogue-world-in-milan-faces-backlash-over-pharmaceutical-sponsorship-amidst-contr-6a1cf175a9a3178dPharmaRadar360en2026-09-27T10:46:53.000ZVogue World in Milan Faces Backlash Over Pharmaceutical Sponsorship Amidst Controversy on Body Imagehttps://www.pharmaradar360.com/article/team-behind-york-biotech-campus-incredibly-proud-as-site-celebrates-its-30th-ann-77c25d393410c9d0PharmaRadar360en2026-09-27T10:45:00.000ZTeam behind York Biotech Campus ‘incredibly proud’ as site celebrates its 30th anniversaryhttps://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-hunan-er-kang-pharmaceutical-co-ltd-class-afdb2e2893faee3fPharmaRadar360en2026-09-27T10:32:18.000ZEnterprise value to EBITDA forward of Hunan Er-Kang Pharmaceutical Co., Ltd. Class A – SZSE:300267https://www.pharmaradar360.com/article/spdr-s-p-biotech-etf-xbi-stock-price-news-quote-and-history-c496072a78141080PharmaRadar360en2026-09-27T10:29:26.000ZSPDR S&P Biotech ETF (XBI) stock price, news, quote and historyhttps://www.pharmaradar360.com/article/fda-nominee-says-vaccines-are-safe-despite-trump-efforts-to-overhaul-childhood-s-a7323e2ace37ae61PharmaRadar360en2026-09-27T10:21:07.000ZFDA nominee says vaccines are safe despite Trump efforts to overhaul childhood shotshttps://www.pharmaradar360.com/article/china-s-advances-in-pharma-create-new-opportunities-for-pakistan-71e3f98bc5800567PharmaRadar360en2026-09-27T10:00:54.000ZChina’s advances in pharma create new opportunities for Pakistanhttps://www.pharmaradar360.com/article/food-safety-laws-exist-but-compliance-remains-a-challenge-maha-fda-76e341dee8887699PharmaRadar360en2026-09-27T09:56:15.000ZFood safety laws exist, but compliance remains a challenge: Maha FDAhttps://www.pharmaradar360.com/article/stakeholders-want-uganda-s-pharmaceutical-import-dependence-to-reduce-650923b2974e4cf3PharmaRadar360en2026-09-27T09:44:19.000ZStakeholders want Uganda’s pharmaceutical import dependence to reducehttps://www.pharmaradar360.com/article/obituary-kim-dong-yeon-former-chairman-of-bukwang-pharmaceutical-02f3b555b012fe12PharmaRadar360en2026-09-27T09:32:00.000ZObituary: Kim Dong-yeon, former chairman of Bukwang Pharmaceuticalhttps://www.pharmaradar360.com/article/four-aim-miners-and-a-biotech-move-from-promise-to-proof-cd427cb1c1513f37PharmaRadar360en2026-09-27T09:31:57.000ZFour AIM Miners And A Biotech Move From Promise To Proofhttps://www.pharmaradar360.com/article/3-numbers-from-viking-therapeutics-weight-loss-drug-trial-that-have-wall-street-25b33acd00c34ed7PharmaRadar360en2026-09-27T09:15:00.000Z3 Numbers From Viking Therapeutics' Weight-Loss Drug Trial That Have Wall Street Buzzinghttps://www.pharmaradar360.com/article/iran-runs-short-of-critical-medicines-as-us-blockade-disrupts-supplies-678826ab8c02692bPharmaRadar360en2026-09-27T08:35:14.000ZIran runs short of critical medicines as US blockade disrupts supplieshttps://www.pharmaradar360.com/article/pakistani-chinese-companies-sign-agreement-to-expand-industrial-and-commercial-l-ef253c1ab605a84fPharmaRadar360en2026-09-27T08:31:13.000ZPakistani, Chinese companies sign agreement to expand industrial and commercial linkageshttps://www.pharmaradar360.com/article/silkway-impex-advances-partnerships-with-chinese-companies-in-infrastructure-pha-84102be3b7efbf7fPharmaRadar360en2026-09-27T08:01:25.000ZSilkway Impex advances partnerships with Chinese companies in infrastructure, pharma, steelhttps://www.pharmaradar360.com/article/what-trump-s-most-favoured-nation-drug-pricing-policy-might-mean-for-canadians-90961d18c1e47354PharmaRadar360en2026-09-27T08:00:00.000ZWhat Trump's 'most favoured nation' drug pricing policy might mean for Canadianshttps://www.pharmaradar360.com/article/pune-fda-seizes-28-53-lakh-worth-of-food-stock-7-licences-suspended-banned-tobac-097befb17b72fc31PharmaRadar360en2026-09-27T07:01:12.000ZPune FDA Seizes ₹28.53 Lakh Worth Of Food Stock; 7 Licences Suspended, Banned Tobacco Worth ₹1.98 Lakhhttps://www.pharmaradar360.com/article/kodiak-sciences-to-report-daybreak-phase-3-results-for-zenkuda-and-ksi-501-73668da8d47bf721PharmaRadar360en2026-09-27T06:38:50.000ZKodiak Sciences to Report DAYBREAK Phase 3 Results for Zenkuda and KSI-501https://www.pharmaradar360.com/article/headlands-research-joins-scrs-global-impact-partner-program-06bae840ca1834b7PharmaRadar360en2026-09-27T06:38:50.000ZHeadlands Research Joins SCRS Global Impact Partner Programhttps://www.pharmaradar360.com/article/5-indian-companies-earning-the-highest-revenue-of-up-to-80-6-from-the-us-20677379732a8072PharmaRadar360en2026-09-27T06:30:38.000Z5 Indian Companies Earning the Highest Revenue of up to 80.6% From the UShttps://www.pharmaradar360.com/article/avianca-cargo-obtains-gdp-pharma-certification-and-strengthens-its-european-netw-486c5e5912a03f41PharmaRadar360en2026-09-27T05:59:11.000ZAvianca Cargo Obtains GDP Pharma Certification and Strengthens Its European Networkhttps://www.pharmaradar360.com/article/sellas-life-sciences-draws-significant-retail-buzz-as-traders-eye-regal-phase-3-8573551db14a7498PharmaRadar360en2026-09-27T05:58:18.000ZSellas Life Sciences Draws Significant Retail Buzz As Traders Eye REGAL Phase 3 Catalyst – SLS Stock Soars 15%https://www.pharmaradar360.com/article/symbiotec-pharmalab-with-57-market-share-across-key-steroid-apis-why-is-it-betti-aaf4ef502ab3b000PharmaRadar360en2026-09-27T04:31:37.000ZSymbiotec Pharmalab: With 57% Market Share Across Key Steroid APIs, Why Is It Betting Big on Insulin and Alternative Proteins?https://www.pharmaradar360.com/article/korea-manufacturing-optimism-broadens-as-chips-hit-record-five-sectors-top-100-c-a48838d30d421051PharmaRadar360en2026-09-27T04:30:00.000ZKorea manufacturing optimism broadens as chips hit record, five sectors top 100 - CHOSUNBIZhttps://www.pharmaradar360.com/article/the-sahrawi-pharmaceutical-lab-battling-against-sand-and-shortages-we-are-a-rose-f0e7205310179a0fPharmaRadar360en2026-09-27T04:00:00.000ZThe Sahrawi pharmaceutical lab battling against sand and shortages: ‘We are a rose in the desert’https://www.pharmaradar360.com/article/t-rowe-price-s-new-active-biotech-and-small-cap-etfs-might-change-the-case-for-i-c51aae51eae3a9daPharmaRadar360en2026-09-27T03:16:00.000ZT. Rowe Price’s New Active Biotech and Small-Cap ETFs Might Change The Case For Investing In TROWhttps://www.pharmaradar360.com/article/hanall-biopharma-halts-lupus-drug-trial-pivots-to-rheumatoid-arthritis-dce1a4ebe83c3499PharmaRadar360en2026-09-27T02:35:00.000ZHanAll Biopharma Halts Lupus Drug Trial, Pivots to Rheumatoid Arthritishttps://www.pharmaradar360.com/article/dftx-vs-cmps-which-stock-has-more-upside-from-trump-s-new-psychedelic-therapy-pu-ef64dcf5e3960581PharmaRadar360en2026-09-27T01:44:48.000ZDFTX Vs CMPS: Which Stock Has More Upside From Trump’s New Psychedelic Therapy Push?https://www.pharmaradar360.com/article/p-cab-makers-turn-to-diabetes-drugs-for-next-growth-engine-da931bb9ed826602PharmaRadar360en2026-09-27T01:00:05.000ZP-CAB Makers Turn to Diabetes Drugs for Next Growth Enginehttps://www.pharmaradar360.com/article/uaeu-emirates-biotech-launch-uae-s-first-organic-waste-valorization-pilot-plant-7776c6508fb95fe0PharmaRadar360en2026-09-27T00:56:55.000ZUAEU & Emirates Biotech launch UAE’s first organic-waste valorization pilot planthttps://www.pharmaradar360.com/article/hanall-biopharma-halts-lupus-bid-pivots-to-arthritis-as-china-setback-deepens-ch-f259b0b68cff907cPharmaRadar360en2026-09-27T00:56:00.000ZHanAll Biopharma halts lupus bid, pivots to arthritis as China setback deepens - CHOSUNBIZhttps://www.pharmaradar360.com/article/livzon-pharmaceutical-shareholders-approve-egm-resolution-clearing-way-for-speci-9470590c6ee1a91dPharmaRadar360en2026-09-27T00:36:55.000ZLivzon Pharmaceutical Shareholders Approve EGM Resolution, Clearing Way for Special Dividendhttps://www.pharmaradar360.com/article/china-pledges-support-for-lanka-s-pharmaceutical-industry-f52fefd8663b323cPharmaRadar360en2026-09-27T00:36:47.000ZChina pledges support for Lanka’s pharmaceutical industryhttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-0073cc37693089ccPharmaRadar360en2026-09-27T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9794-4-crore-consolidated-revenue-and-e2-82-b9206-5-crore-o-386ab1b37c72e551PharmaRadar360en2026-09-27T00:00:00.000Znatco records %e2%82%b9794 4 crore consolidated revenue and %e2%82%b9206 5 crore of profit after tax for q1 fy27https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-7dacac758d0d3053PharmaRadar360en2026-09-27T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-2740f768167242e3PharmaRadar360en2026-09-27T00:00:00.000Znatco receives tentative approval for olaparib tablets from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-bc1f335f6e2b62d7PharmaRadar360en2026-09-27T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-730f005fc3219c9fPharmaRadar360en2026-09-27T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-06eb02a90ebbe6c4PharmaRadar360en2026-09-27T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-1e46567a43e33af6PharmaRadar360en2026-09-27T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-limited-announces-conclusion-of-us-fda-inspection-at-visakhapatnam-9f9fb01bc82c93ddPharmaRadar360en2026-09-27T00:00:00.000Znatco pharma limited announces conclusion of us fda inspection at visakhapatnam andhra pradesh finished dosage formulations fdf unithttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-66cdfdf01048dc1bPharmaRadar360en2026-09-27T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-ac6b0305dbd84a67PharmaRadar360en2026-09-27T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-ae54dab992c6feffPharmaRadar360en2026-09-27T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/investment-of-us-14-million-in-egenesis-inc-by-natco-pharma-canada-inc-and-natco-833cdcaaea220bc8PharmaRadar360en2026-09-27T00:00:00.000Zinvestment of us 14 million in egenesis inc by natco pharma canada inc and natco pharma south africa proprietary limitedhttps://www.pharmaradar360.com/article/home-page-5db4a19242a7e626PharmaRadar360en2026-09-27T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/advanced-bioinformatics-tools-and-computational-strategies-for-drug-discovery-in-3afa13723fa96826PharmaRadar360en2026-09-27T00:00:00.000ZAdvanced Bioinformatics Tools and Computational Strategies for Drug Discovery in Biomedical Scienceshttps://www.pharmaradar360.com/article/development-and-characterization-of-gastroretentive-floating-tablets-of-domperid-0d241e2c57378bc1PharmaRadar360en2026-09-27T00:00:00.000ZDEVELOPMENT AND CHARACTERIZATION OF GASTRORETENTIVE FLOATING TABLETS OF DOMPERIDONE MALEATE AND FAMOTIDINE USING HYDROPHILIC POLYMER MATRIX.https://www.pharmaradar360.com/article/development-optimization-and-characterization-of-a-cow-ghee-based-doxorubicin-na-e0bc74f6a122120cPharmaRadar360en2026-09-27T00:00:00.000ZDEVELOPMENT, OPTIMIZATION AND CHARACTERIZATION OF A COW GHEE-BASED DOXORUBICIN NANOEMULSION FOR ENHANCED DRUG DELIVERY IN LUNG CANCERhttps://www.pharmaradar360.com/article/evaluating-pharmacovigilance-awareness-and-adverse-drug-reaction-reporting-among-2d11e592eb6eff42PharmaRadar360en2026-09-27T00:00:00.000ZEVALUATING PHARMACOVIGILANCE AWARENESS AND ADVERSE DRUG REACTION REPORTING AMONG UNDERGRADUATE HEALTHCARE STUDENTS FOLLOWING A STRUCTURED EDUCATIONAL PROGRAMMEhttps://www.pharmaradar360.com/article/transcorneal-permeation-enhancement-of-moxifloxacin-using-amino-acid-co-evaporat-cbd5fe512ea7d227PharmaRadar360en2026-09-27T00:00:00.000ZTRANSCORNEAL PERMEATION ENHANCEMENT OF MOXIFLOXACIN USING AMINO ACID CO-EVAPORATED SYSTEMShttps://www.pharmaradar360.com/article/formulation-and-evaluation-of-drotaverine-hcl-and-mefenamic-acid-dispersible-tab-fe581e054794766aPharmaRadar360en2026-09-27T00:00:00.000ZFORMULATION AND EVALUATION OF DROTAVERINE HCL AND MEFENAMIC ACID DISPERSIBLE TABLETShttps://www.pharmaradar360.com/article/generative-artificial-intelligence-in-internal-medicine-applications-in-clinical-fbe85a0850aa8680PharmaRadar360en2026-09-27T00:00:00.000ZGenerative Artificial Intelligence in Internal Medicine: Applications in Clinical Reasoning, Differential Diagnosis, and Clinical Decision-Makinghttps://www.pharmaradar360.com/article/comprehensive-evaluation-of-tetralogy-of-fallot-superior-diagnostic-performance-028235781b32defaPharmaRadar360en2026-09-27T00:00:00.000ZComprehensive Evaluation of Tetralogy of Fallot: Superior Diagnostic Performance and Clinical Utility of MDCT Compared to Echocardiographyhttps://www.pharmaradar360.com/article/generative-ai-in-nursing-education-nurse-educators-perceptions-of-readiness-trus-87d4fec32d08b53aPharmaRadar360en2026-09-27T00:00:00.000ZGenerative AI in Nursing Education: Nurse Educators' Perceptions of Readiness, Trust, and Clinical Judgmenthttps://www.pharmaradar360.com/article/sex-stratified-sociodemographic-and-clinical-profile-of-maintenance-hemodialysis-1c74159e77415272PharmaRadar360en2026-09-27T00:00:00.000ZSex-Stratified Sociodemographic and Clinical Profile of Maintenance Hemodialysis Patients at a Remote Island Hospital in Bali: A Cross-Sectional Studyhttps://www.pharmaradar360.com/article/implementation-science-in-the-pharmaceutical-industry-why-we-know-which-innovati-c65a1a72e27ff304PharmaRadar360en2026-09-27T00:00:00.000ZImplementation Science in the Pharmaceutical Industry: Why we Know which Innovations Work but Still Cannot Implement Them - A Comparative Review of the United States, the European Union, and International Regulatory Contextshttps://www.pharmaradar360.com/article/digital-transformation-of-pharmaceutical-production-planning-in-saudi-arabia-usi-86037df7245c33c2PharmaRadar360en2026-09-27T00:00:00.000ZDigital Transformation of Pharmaceutical Production Planning in Saudi Arabia Using Integrated ERP Systemshttps://www.pharmaradar360.com/article/development-and-internal-validation-of-a-simplified-clinical-risk-score-for-syst-8adc1040d4a8bb90PharmaRadar360en2026-09-27T00:00:00.000ZDevelopment and Internal Validation of a Simplified Clinical Risk Score for Systemic Complications After Spine Surgery Using a Nationwide Japanese Registry: JOANR/JSSR-DBhttps://www.pharmaradar360.com/article/performance-evaluation-of-the-latest-general-purpose-large-language-models-in-me-76836b41c18c47f5PharmaRadar360en2026-09-27T00:00:00.000ZPerformance Evaluation of the Latest General-Purpose Large Language Models in Medical Reasoning and Clinical Screening Taskshttps://www.pharmaradar360.com/article/clinical-factors-associated-with-implant-removal-following-surgical-site-infecti-a92e90264ffdf7f7PharmaRadar360en2026-09-27T00:00:00.000ZClinical Factors Associated with Implant Removal Following Surgical Site Infection after Spinal Instrumentation Surgery for Lumbar Degenerative Diseasehttps://www.pharmaradar360.com/article/temporal-observations-of-multifidus-muscle-injury-and-degeneration-following-pos-a0c5621a3a0b98a7PharmaRadar360en2026-09-27T00:00:00.000ZTemporal Observations of Multifidus Muscle Injury and Degeneration Following Posterior Thoracolumbar Spine Surgery: A Clinical Histological Study over a Three-Year Time Periodhttps://www.pharmaradar360.com/article/relationship-between-postoperative-neuropathic-pain-and-clinical-scores-in-patie-623d4cd1eb315f38PharmaRadar360en2026-09-27T00:00:00.000ZRelationship between Postoperative Neuropathic Pain and Clinical Scores in Patients with Cervical Ossification of the Posterior Longitudinal Ligamenthttps://www.pharmaradar360.com/article/successful-limb-salvage-in-pediatric-nicolau-syndrome-following-intramuscular-be-b27aefb2659bd628PharmaRadar360en2026-09-27T00:00:00.000ZSuccessful Limb Salvage in Pediatric Nicolau Syndrome Following Intramuscular Benzathine Penicillin: A Case Reporthttps://www.pharmaradar360.com/article/serial-endoscopic-decompression-in-recurrent-sigmoid-volvulus-temporary-success-045557902e681105PharmaRadar360en2026-09-27T00:00:00.000ZSerial Endoscopic Decompression in Recurrent Sigmoid Volvulus: Temporary Success, Definitive Failurehttps://www.pharmaradar360.com/article/palmar-surprise-a-case-of-eccrine-poroma-with-review-of-literature-daaca22520e188d4PharmaRadar360en2026-09-27T00:00:00.000ZPalmar Surprise: A Case of Eccrine Poroma with Review of Literature.https://www.pharmaradar360.com/article/seizure-and-stroke-in-a-patient-with-down-syndrome-diagnosed-with-moyamoya-syndr-3a20d6c05b0b6babPharmaRadar360en2026-09-27T00:00:00.000ZSeizure and Stroke in a Patient with Down Syndrome Diagnosed with Moyamoya Syndrome: A Case Reporthttps://www.pharmaradar360.com/article/diagnostic-approach-and-therapeutic-interventions-in-ogilvie-syndrome-in-burn-pa-ac7dd47ea16c724bPharmaRadar360en2026-09-27T00:00:00.000ZDiagnostic Approach and Therapeutic Interventions in Ogilvie Syndrome in Burn Patients: A Report of Two Clinical Caseshttps://www.pharmaradar360.com/article/performance-optimization-focused-family-behavior-therapy-to-address-verbal-and-p-2b928b64016041f6PharmaRadar360en2026-09-27T00:00:00.000ZPerformance Optimization-Focused Family Behavior Therapy to Address Verbal and Physical Aggression in an Adolescent Diagnosed With Bipolar I Disorder: A Case Reporthttps://www.pharmaradar360.com/article/validation-of-the-estonian-versions-of-the-pediatric-symptom-checklist-17-youth-09184cc1a6ddd197PharmaRadar360en2026-09-27T00:00:00.000ZValidation of the Estonian Versions of the Pediatric Symptom Checklist-17 Youth Self-Report and Parent Reporthttps://www.pharmaradar360.com/article/from-institutional-experience-to-evidence-based-standards-for-psychiatric-app-pr-9511801540a64b68PharmaRadar360en2026-09-27T00:00:00.000ZFrom Institutional Experience to Evidence-Based Standards for Psychiatric APP Practicehttps://www.pharmaradar360.com/article/personalised-drug-recommender-systems-based-on-electronic-health-records-reprodu-84af5521dd6aed0fPharmaRadar360en2026-09-27T00:00:00.000ZPersonalised Drug Recommender Systems based on Electronic Health Records: Reproducibility and External Validityhttps://www.pharmaradar360.com/article/letter-to-the-editor-comment-on-the-impact-of-virtual-reality-with-relaxation-mu-794e3420b164396dPharmaRadar360en2026-09-27T00:00:00.000ZLetter to the Editor: Comment on “The Impact of Virtual Reality With Relaxation Music and Distraction Cards on Pain, Anxiety, and Satisfaction Levels of Women With an Intrauterine Device: A Randomized Controlled Trial”https://www.pharmaradar360.com/article/clinical-and-therapeutic-relevance-of-b7-h3-in-sarcomas-molecular-insights-from-71c941cdfd99a2a9PharmaRadar360en2026-09-27T00:00:00.000ZClinical and Therapeutic Relevance of B7-H3 in Sarcomas: Molecular Insights from a Systematic Reviewhttps://www.pharmaradar360.com/article/novel-cocrystal-inclusion-compound-of-bezafibrate-with-l-proline-preparation-cha-99ada7b94343909dPharmaRadar360en2026-09-27T00:00:00.000ZNovel cocrystal inclusion compound of bezafibrate with L-proline: preparation, characterization and in vitro/in vivo evaluationhttps://www.pharmaradar360.com/article/a-prospective-split-scar-randomized-controlled-trial-of-post-operative-silicone-fbe5117ebfc29a56PharmaRadar360en2026-09-27T00:00:00.000ZA prospective split-scar randomized controlled trial of post-operative silicone tape improves scar appearancehttps://www.pharmaradar360.com/article/osteosarcopenia-and-stability-of-fragility-pelvic-fractures-in-elderly-women-e4a493ef22b69abdPharmaRadar360en2026-09-27T00:00:00.000ZOsteosarcopenia and stability of fragility pelvic fractures in elderly womenhttps://www.pharmaradar360.com/article/novel-benzenesulfonamide-derivatives-as-larvicidal-and-antibacterial-agents-insi-35c10e7f4c527631PharmaRadar360en2026-09-27T00:00:00.000ZNovel benzenesulfonamide derivatives as larvicidal and antibacterial agents: insights from histopathological studies, molecular docking, and ADMET profilinghttps://www.pharmaradar360.com/article/mindful-eating-as-a-supportive-intervention-for-breast-cancer-survivors-a-pilot-6310ebfdeb068ec4PharmaRadar360en2026-09-27T00:00:00.000ZMindful eating as a supportive intervention for breast cancer survivors: a pilot randomized controlled trialhttps://www.pharmaradar360.com/article/hyperbaric-oxygen-therapy-as-an-adjunct-to-combined-oral-and-intratympanic-stero-2319ef287109c45fPharmaRadar360en2026-09-27T00:00:00.000ZHyperbaric Oxygen Therapy as an adjunct to Combined Oral and Intratympanic Steroids in Sudden Sensorineural Hearing Loss: A Randomized Clinical Trialhttps://www.pharmaradar360.com/article/molecular-identification-and-resistance-associated-gene-profiling-of-non-tubercu-a204bee6a51b8845PharmaRadar360en2026-09-27T00:00:00.000ZMolecular identification and resistance-associated gene profiling of non-tuberculous mycobacteria isolated from bovine clinical sampleshttps://www.pharmaradar360.com/article/clinical-features-in-children-with-loss-of-autism-diagnosis-and-persistent-autis-a8eb6187a65d377bPharmaRadar360en2026-09-27T00:00:00.000ZClinical Features in Children With Loss of Autism Diagnosis and Persistent Autism: A Comparative Studyhttps://www.pharmaradar360.com/article/nlrp3-inflammasome-inhibitors-as-precision-anti-inflammatory-pharmacotherapy-tra-21a39a95b16799d3PharmaRadar360en2026-09-27T00:00:00.000ZNLRP3 Inflammasome Inhibitors as Precision Anti-inflammatory Pharmacotherapy: Translational Advances, Clinical Evidence, and Disease-specific Challengeshttps://www.pharmaradar360.com/article/clinical-outcomes-during-concurrent-dupilumab-and-advanced-immune-modifying-ther-4ab55882ee92189bPharmaRadar360en2026-09-27T00:00:00.000ZClinical Outcomes During Concurrent Dupilumab and Advanced Immune-Modifying Therapy: A Real-World Cohort Studyhttps://www.pharmaradar360.com/article/the-prevalence-of-iga-nephropathy-in-japan-results-from-a-nationwide-survey-2ba8cf92e2c60190PharmaRadar360en2026-09-27T00:00:00.000ZThe prevalence of IgA nephropathy in Japan: results from a nationwide surveyhttps://www.pharmaradar360.com/article/association-between-abcg2-transporter-functionality-and-ckd-progression-a-retros-dc765de069efc1faPharmaRadar360en2026-09-27T00:00:00.000ZAssociation between ABCG2 transporter functionality and CKD progression: a retrospective cohort study in patients with CKD stage G3https://www.pharmaradar360.com/article/outcome-of-lumbar-fusion-with-template-guided-cortical-bone-trajectory-versus-tr-97ac0a6a9180565dPharmaRadar360en2026-09-27T00:00:00.000ZOutcome of lumbar fusion with template-guided cortical bone trajectory versus traditional pedicle screw trajectory – a prospective randomized trialhttps://www.pharmaradar360.com/article/combination-therapy-with-furosemide-and-metolazone-as-compared-to-furosemide-alo-de1fcda960bd54a1PharmaRadar360en2026-09-27T00:00:00.000ZCombination therapy with furosemide and metolazone as compared to furosemide alone for treatment of edema in children with nephrotic syndrome: a randomized controlled trialhttps://www.pharmaradar360.com/article/efficacy-and-safety-of-adjuvant-sintilimab-monotherapy-in-high-risk-resected-eso-7e898f4d23ff8327PharmaRadar360en2026-09-27T00:00:00.000ZEfficacy and safety of adjuvant sintilimab monotherapy in high-risk resected esophageal squamous cell carcinoma: a prospective, single-arm phase II trialhttps://www.pharmaradar360.com/article/pressure-distribution-in-supine-postures-full-body-and-region-of-interest-analys-c6d302956be0d517PharmaRadar360en2026-09-27T00:00:00.000ZPressure Distribution in Supine Postures: Full-Body and Region of Interest Analysishttps://www.pharmaradar360.com/article/dino-by-paperbox-a-serious-gaming-platform-for-early-screening-of-learning-diffi-2194f2a855ef89a8PharmaRadar360en2026-09-27T00:00:00.000ZDINO by Paperbox: A Serious-Gaming Platform for Early Screening of Learning Difficulties in Childrenhttps://www.pharmaradar360.com/article/resting-hrv-signatures-of-psychological-burden-time-of-day-modulation-across-anx-d4ee4f19d5ea4d09PharmaRadar360en2026-09-27T00:00:00.000ZResting HRV Signatures of Psychological Burden: Time-of-Day Modulation across Anxiety, Stress, and Distresshttps://www.pharmaradar360.com/article/biomimetic-hyaluronic-acid-based-scaffolds-for-tissue-engineering-applications-b9a3e7220b0282e1PharmaRadar360en2026-09-27T00:00:00.000ZBiomimetic Hyaluronic Acid-Based Scaffolds for Tissue Engineering Applicationshttps://www.pharmaradar360.com/article/multifunctional-magnetofluorescent-carbon-dots-for-magnetic-hyperthermia-in-brea-8324b5a2c83f5066PharmaRadar360en2026-09-27T00:00:00.000ZMultifunctional Magnetofluorescent Carbon Dots for Magnetic Hyperthermia in Breast Cancer Modelshttps://www.pharmaradar360.com/article/pharmacoeconomic-analysis-of-noac-therapy-in-the-prevention-of-stroke-in-patient-937bb0adff7243a5PharmaRadar360en2026-09-27T00:00:00.000ZPharmacoeconomic Analysis of NOAC Therapy in the Prevention of Stroke in Patients with Atrial Fibrillationhttps://www.pharmaradar360.com/article/pillsguard-an-iot-based-system-for-safe-medication-administration-and-error-redu-b6c07865c3c77edfPharmaRadar360en2026-09-27T00:00:00.000ZPillsGuard: An IoT-Based System for Safe Medication Administration and Error Reduction in Clinical Environmentshttps://www.pharmaradar360.com/article/a-novel-iterative-image-reconstruction-method-for-low-dose-ct-based-on-artificia-5324af9f5c996f94PharmaRadar360en2026-09-27T00:00:00.000ZA Novel Iterative Image Reconstruction Method for Low-Dose CT based on Artificial Neural Networkshttps://www.pharmaradar360.com/article/microwave-medical-imaging-for-colorectal-cancer-detection-electromagnetic-simula-7a46a8758e5110cdPharmaRadar360en2026-09-27T00:00:00.000ZMicrowave Medical Imaging for Colorectal Cancer Detection: Electromagnetic Simulations and Tissue-Mimicking Material Fabricationhttps://www.pharmaradar360.com/article/a-patient-specific-flow-enabled-ultrasound-phantom-for-femoral-vascular-access-t-e393e485ff0d0af9PharmaRadar360en2026-09-27T00:00:00.000ZA Patient-Specific Flow-Enabled Ultrasound Phantom for Femoral Vascular Access Traininghttps://www.pharmaradar360.com/article/proof-of-concept-multilevel-linguistic-assessment-and-fmri-based-analysis-of-bra-e67de1c534849cf2PharmaRadar360en2026-09-27T00:00:00.000ZProof of Concept: Multilevel Linguistic Assessment and fMRI-Based Analysis of Brain Regions Involved in Language Learning in University-Level Studentshttps://www.pharmaradar360.com/article/feasibility-of-a-mixed-reality-framework-for-balance-assessment-in-multiple-scle-62482be7fcd59bf7PharmaRadar360en2026-09-27T00:00:00.000ZFeasibility of a Mixed Reality Framework for Balance Assessment in Multiple Sclerosishttps://www.pharmaradar360.com/article/from-users-to-co-creators-advancing-usability-in-medical-device-development-510c9555ffa129f3PharmaRadar360en2026-09-27T00:00:00.000ZFrom Users to Co‑Creators: Advancing Usability in Medical Device Developmenthttps://www.pharmaradar360.com/article/design-and-preliminary-testing-of-an-event-triggered-mixed-reality-system-for-at-6eebfa554bdf767ePharmaRadar360en2026-09-27T00:00:00.000ZDesign and Preliminary Testing of an Event-Triggered Mixed Reality System for Ataxia Assessmenthttps://www.pharmaradar360.com/article/quantitative-assessment-of-crossed-cerebellar-diaschisis-in-ischemic-stroke-usin-0aa19309d2652264PharmaRadar360en2026-09-27T00:00:00.000ZQuantitative Assessment of Crossed Cerebellar Diaschisis in Ischemic Stroke Using a CT Perfusion Normalization Frameworkhttps://www.pharmaradar360.com/article/static-and-motion-adaptive-temporal-propagation-for-vessel-segmentation-in-therm-d39bbee46391e36aPharmaRadar360en2026-09-27T00:00:00.000ZStatic and Motion-Adaptive Temporal Propagation for Vessel Segmentation in Thermal Infrared Videoshttps://www.pharmaradar360.com/article/detection-of-pressure-induced-faults-in-continuous-glucose-monitoring-sensors-us-ab623d40dd7413b3PharmaRadar360en2026-09-27T00:00:00.000ZDetection of Pressure-Induced Faults in Continuous Glucose Monitoring Sensors Using a Dynamic Time Warping-Based Approachhttps://www.pharmaradar360.com/article/sealed-rare-gas-system-for-cold-atmospheric-plasma-and-electromagnetic-energy-de-47adbde79d90ce85PharmaRadar360en2026-09-27T00:00:00.000ZSealed Rare-Gas System for Cold Atmospheric Plasma and Electromagnetic Energy Deliveryhttps://www.pharmaradar360.com/article/differentiating-cognitive-workload-requests-by-combined-behavioural-performance-5a634e7c81db0f63PharmaRadar360en2026-09-27T00:00:00.000ZDifferentiating Cognitive Workload Requests by Combined Behavioural Performance and HRV Metricshttps://www.pharmaradar360.com/article/data-driven-smart-clinical-engineering-a-multidimensional-assessment-of-patient-ba259059d9b88e7dPharmaRadar360en2026-09-27T00:00:00.000ZData-Driven Smart Clinical Engineering: A Multidimensional Assessment of Patient Safety, Operational Ethics, and ESG Sustainabilityhttps://www.pharmaradar360.com/article/additive-manufacturing-of-biocompatible-oculopalpebral-prostheses-a-workflow-for-d22293d0ede73b2bPharmaRadar360en2026-09-27T00:00:00.000ZAdditive Manufacturing of Biocompatible Oculopalpebral Prostheses: A Workflow for Personalized Design Approach to Reduce Clinical Timehttps://www.pharmaradar360.com/article/digital-training-platform-for-biomedical-equipment-management-412e27c0774d5ea1PharmaRadar360en2026-09-27T00:00:00.000ZDigital Training Platform for Biomedical Equipment Managementhttps://www.pharmaradar360.com/article/building-a-national-medical-equipment-inventory-in-greece-field-registration-pro-c85160ee567d0018PharmaRadar360en2026-09-27T00:00:00.000ZBuilding a National Medical Equipment Inventory in Greece: Field Registration Process and AI-Assisted Data Entry Across 129 Public Hospitalshttps://www.pharmaradar360.com/article/an-event-based-approach-to-estimate-motor-engagement-during-robot-assisted-gait-a8e565b6e7f874eaPharmaRadar360en2026-09-27T00:00:00.000ZAn Event-Based Approach to Estimate Motor Engagement During Robot-Assisted Gait Training Via Gaze-Related Featureshttps://www.pharmaradar360.com/article/a-practical-handheld-photoacoustic-microscopy-system-for-in-vivo-microvascular-i-0a3e005def802245PharmaRadar360en2026-09-27T00:00:00.000ZA Practical Handheld Photoacoustic Microscopy System for In Vivo Microvascular Imaginghttps://www.pharmaradar360.com/article/advancing-in-vivo-chimeric-antigen-receptor-t-cell-engineering-to-accelerate-cli-3fa8563db73df733PharmaRadar360en2026-09-27T00:00:00.000ZAdvancing In Vivo Chimeric Antigen Receptor T‐Cell Engineering to Accelerate Clinical Translationhttps://www.pharmaradar360.com/article/what-are-the-benefits-and-harms-of-topical-cyclosporine-a-csa-0-05-for-people-wi-8d78566a5462f875PharmaRadar360en2026-09-27T00:00:00.000ZWhat are the benefits and harms of topical cyclosporine A (CsA) 0.05% for people with dry eye disease?https://www.pharmaradar360.com/article/for-adults-with-endometriosis-associated-pain-what-are-the-benefits-and-harms-of-68a72cbd94d48be1PharmaRadar360en2026-09-27T00:00:00.000ZFor adults with endometriosis-associated pain, what are the benefits and harms of daily oral progestogens compared with daily oral contraceptives?https://www.pharmaradar360.com/article/how-does-surgery-plus-systemic-treatment-compare-with-systemic-treatment-alone-f-ed3df23cb32b763aPharmaRadar360en2026-09-27T00:00:00.000ZHow does surgery plus systemic treatment compare with systemic treatment alone for women with metastatic breast cancer?https://www.pharmaradar360.com/article/araceli-biosciences-showcases-endeavor-imaging-system-at-mbc-biolabs-4c6a8304665c3dfcPharmaRadar360en2026-09-26T23:54:40.000ZAraceli Biosciences Showcases Endeavor Imaging System at MBC BioLabshttps://www.pharmaradar360.com/article/excipient-selection-strategies-to-mitigate-nitrosamine-risks-812ded3585d60c32PharmaRadar360en2026-09-26T23:22:21.000ZExcipient Selection Strategies to Mitigate Nitrosamine Riskshttps://www.pharmaradar360.com/article/daewoong-pharmaceutical-reveals-full-phase-2-trial-patient-data-for-ipf-drug-can-1b1d09e6ea1a1f01PharmaRadar360en2026-09-26T23:10:00.000ZDaewoong Pharmaceutical reveals full Phase 2 trial patient data for IPF drug candidate ‘Bersiporocin’ for the first timehttps://www.pharmaradar360.com/article/juniper-biosciences-receives-u-s-fda-breakthrough-therapy-designation-for-jbs-00-0da8c40634f4117cPharmaRadar360en2026-09-26T23:00:16.000ZJuniper Biosciences Receives U.S. FDA Breakthrough Therapy Designation for JBS-003 - MSKhttps://www.pharmaradar360.com/article/azetukalner-nda-submitted-ema-gives-approval-recommendation-to-ocrelizumab-phase-0f38194b2abaa2ddPharmaRadar360en2026-09-26T22:45:02.000ZAzetukalner NDA Submitted, EMA Gives Approval Recommendation to Ocrelizumab, Phase 3 FUSION Trial Meets End Points | NeurologyLive - Clinical Neurology News and Neurology Expert Insightshttps://www.pharmaradar360.com/article/food-safety-laws-exist-but-compliance-remains-a-challenge-maha-fda-af828665f42c5918PharmaRadar360en2026-09-26T22:31:27.000ZFood safety laws exist, but compliance remains a challenge: Maha FDAhttps://www.pharmaradar360.com/article/europe-injects-capital-into-colombian-biotech-firm-to-produce-250-million-vaccin-feb9a50256af0dcaPharmaRadar360en2026-09-26T22:31:00.000ZEurope Injects Capital into Colombian Biotech Firm to Produce 250 Million Vaccineshttps://www.pharmaradar360.com/article/grail-s-galleri-cancer-test-clears-fda-panel-on-safety-narrowly-backed-on-effect-a5d5ca427ce499d3PharmaRadar360en2026-09-26T22:17:39.000ZGRAIL's Galleri Cancer Test Clears FDA Panel On Safety, Narrowly Backed On Effectiveness: GRAL Stock In Focushttps://www.pharmaradar360.com/article/west-pharmaceutical-slides-as-glp-1-trade-cools-77e252e2e7686b78PharmaRadar360en2026-09-26T22:15:25.000ZWest Pharmaceutical Slides As GLP-1 Trade Coolshttps://www.pharmaradar360.com/article/amgen-stock-forecast-amgn-reclaims-410-as-pipeline-catalysts-build-7fbfcc7551885f60PharmaRadar360en2026-09-26T22:01:25.000ZAmgen Stock Forecast: AMGN Reclaims $410 as Pipeline Catalysts Buildhttps://www.pharmaradar360.com/article/how-burning-rock-biotech-limited-bnr-affects-rotational-strategy-timing-f96bf4516451454fPharmaRadar360en2026-09-26T21:18:02.000ZHow Burning Rock Biotech Limited (BNR) Affects Rotational Strategy Timinghttps://www.pharmaradar360.com/article/waters-tops-growth-outlook-as-ai-demand-bd-integration-fuel-momentum-fd91aa9b29e1acd8PharmaRadar360en2026-09-26T21:02:03.000ZWaters Tops Growth Outlook as AI Demand, BD Integration Fuel Momentumhttps://www.pharmaradar360.com/article/parkinson-drug-race-accelerates-as-lecun-sk-biopharm-roche-advance-chosunbiz-3ec3f140ea8d2dcfPharmaRadar360en2026-09-26T21:00:00.000ZParkinson drug race accelerates as LeCun, SK Biopharm, Roche advance - CHOSUNBIZhttps://www.pharmaradar360.com/article/no-2026-1269-public-health-warning-against-the-purchase-and-use-of-the-unregiste-2debac0e0a4f420fPharmaRadar360en2026-09-26T20:59:40.000ZNo.2026-1269 || Public Health Warning Against the Purchase and Use of the Unregistered Drug Product “Shira Yuki Beauty Is Power Ultimate Anti-aging and Whitening 180,000 mg i.m./i.v.” - Food and Drug Administrationhttps://www.pharmaradar360.com/article/nccn-journal-publishes-guidelines-update-in-mantle-cell-lymphoma-795f7701a8116285PharmaRadar360en2026-09-26T20:52:13.000ZNCCN Journal Publishes Guidelines Update in Mantle Cell Lymphomahttps://www.pharmaradar360.com/article/these-two-biotech-stocks-hit-fresh-52-week-highs-today-ntra-clocks-best-day-in-n-714beaedc7ee61b2PharmaRadar360en2026-09-26T20:51:19.000ZThese Two Biotech Stocks Hit Fresh 52-Week Highs Today – NTRA Clocks Best Day In Nearly 20 Monthshttps://www.pharmaradar360.com/article/biomarin-pharmaceutical-bmrn-adds-robert-plenge-to-its-board-4edf4740359ab614PharmaRadar360en2026-09-26T20:42:30.000ZBioMarin Pharmaceutical (BMRN) Adds Robert Plenge To Its Boardhttps://www.pharmaradar360.com/article/sylvia-ortega-martinez-appointed-cdmo-scouting-business-development-director-ame-8e1509594a9436a8PharmaRadar360en2026-09-26T20:29:10.000ZSylvia Ortega Martinez Appointed CDMO Scouting & Business Development Director, Americas at EUROAPIhttps://www.pharmaradar360.com/article/solara-tightens-kyc-norms-for-physical-shareholders-under-sebi-mandate-73d7255028bee488PharmaRadar360en2026-09-26T19:26:04.000ZSolara Tightens KYC Norms for Physical Shareholders Under SEBI Mandatehttps://www.pharmaradar360.com/article/imvax-glioblastoma-data-backs-move-toward-phase-3-trial-955e35904ca54980PharmaRadar360en2026-09-26T19:12:29.000ZImvax Glioblastoma Data Backs Move Toward Phase 3 Trialhttps://www.pharmaradar360.com/article/salvador-carlucci-appointed-chief-executive-officer-at-avizum-ai-0869f7c60b4c3ac5PharmaRadar360en2026-09-26T18:57:31.000ZSalvador Carlucci Appointed Chief Executive Officer at AVIZUM.AIhttps://www.pharmaradar360.com/article/vktx-stock-lags-glp-1-peers-in-july-but-viking-ceo-says-its-obesity-drug-could-o-55e28e0768872cf0PharmaRadar360en2026-09-26T17:40:53.000ZVKTX Stock Lags GLP-1 Peers In July — But Viking CEO Says Its Obesity Drug Could Offer What Rivals Can’thttps://www.pharmaradar360.com/article/post-mi-heart-failure-prevention-intracoronary-mesenchymal-stem-cell-phase-3-tri-cfd907156a7043cePharmaRadar360en2026-09-26T17:18:43.000ZPost-MI heart failure prevention: intracoronary mesenchymal stem cell phase 3 trial retractedhttps://www.pharmaradar360.com/article/dbt-ils-bioincubator-hosts-startup-career-fair-bringing-17-ventures-together-in-4c4084fb98df1ba4PharmaRadar360en2026-09-26T17:08:47.000ZDBT-ILS Bioincubator Hosts Startup Career Fair, Bringing 17 Ventures Together in Bhubaneswarhttps://www.pharmaradar360.com/article/top-biotech-stocks-to-add-to-your-watchlist-september-26th-8ef2ab914c9a2348PharmaRadar360en2026-09-26T17:08:24.000ZTop Biotech Stocks To Add to Your Watchlist - September 26thhttps://www.pharmaradar360.com/article/sun-pharmaceutical-industries-secures-shareholder-approval-for-shareholder-categ-94f0a8f68750daa8PharmaRadar360en2026-09-26T16:56:10.000ZSun Pharmaceutical Industries secures shareholder approval for shareholder category reclassificationhttps://www.pharmaradar360.com/article/navigating-biopharma-complexity-why-long-term-partnerships-matter-39b1115d3c1f4806PharmaRadar360en2026-09-26T16:46:52.000ZNavigating Biopharma Complexity: Why Long-Term Partnerships Matterhttps://www.pharmaradar360.com/article/50-pro-life-leaders-ask-fda-to-restore-abortion-pill-safeguards-3c8a9605a983c3f5PharmaRadar360en2026-09-26T16:00:00.000Z50 pro-life leaders ask FDA to restore abortion pill safeguardshttps://www.pharmaradar360.com/article/kerala-to-overhaul-kmscl-medicine-procurement-new-tenders-from-oct-substandard-d-e6f09e5fd85e2d1aPharmaRadar360en2026-09-26T15:58:26.000ZKerala to overhaul KMSCL medicine procurement; new tenders from Oct, substandard drug suppliers to be blacklistedhttps://www.pharmaradar360.com/article/influence-carries-responsibility-maha-fda-backs-prez-murmu-s-message-to-film-sta-42308c55eae682a8PharmaRadar360en2026-09-26T15:33:41.000Z‘Influence Carries Responsibility’: Maha FDA Backs Prez Murmu’s Message To Film Starshttps://www.pharmaradar360.com/article/rare-diseases-when-patients-drive-the-pharmaceutical-industry-forward-11bc97e6b3da333aPharmaRadar360en2026-09-26T15:23:38.000ZRare diseases: when patients drive the pharmaceutical industry forwardhttps://www.pharmaradar360.com/article/drug-chain-needs-more-checks-not-fewer-links-say-pharmacists-5fd312141c985abePharmaRadar360en2026-09-26T15:21:00.000ZDrug chain needs more checks, not fewer links, say pharmacistshttps://www.pharmaradar360.com/article/aarti-drugs-shares-strategic-growth-plans-at-41st-annual-general-meeting-403fdd2404c5095dPharmaRadar360en2026-09-26T14:58:35.000ZAarti Drugs shares strategic growth plans at 41st Annual General Meetinghttps://www.pharmaradar360.com/article/mundhe-says-food-safety-regulations-are-there-non-compliance-is-biggest-issue-2388734a4081e7dePharmaRadar360en2026-09-26T14:29:14.000ZMundhe says food safety regulations are there, non-compliance is biggest issuehttps://www.pharmaradar360.com/article/nigeria-strengthens-pharmaceutical-sector-059cc79d0a191956PharmaRadar360en2026-09-26T14:28:43.000ZNigeria Strengthens Pharmaceutical Sectorhttps://www.pharmaradar360.com/article/9th-annual-dart-to-the-finish-charity-walk-set-for-saturday-oct-3-at-tod-s-point-81a0b58709f75524PharmaRadar360en2026-09-26T14:20:06.000Z9th Annual DART to the Finish Charity Walk Set for Saturday, Oct 3 at Tod’s Pointhttps://www.pharmaradar360.com/article/tozorakimab-reduces-copd-exacerbations-in-phase-3-trials-7f83549668471ce8PharmaRadar360en2026-09-26T14:07:14.000ZTozorakimab Reduces COPD Exacerbations in Phase 3 Trialshttps://www.pharmaradar360.com/article/amylyx-pharmaceuticals-inc-amlx-stock-price-news-quote-history-789e68f08611ad33PharmaRadar360en2026-09-26T14:04:28.000ZAmylyx Pharmaceuticals, Inc. (AMLX) Stock Price, News, Quote & Historyhttps://www.pharmaradar360.com/article/the-fda-just-rushed-out-emergency-treatments-against-a-parasite-that-can-reach-h-8ca0b03aaf8b0074PharmaRadar360en2026-09-26T14:00:00.000ZThe FDA Just Rushed Out Emergency Treatments Against a Parasite That Can Reach Humanshttps://www.pharmaradar360.com/article/people-don-t-realise-how-food-safety-lapses-risk-public-health-mundhe-96d9e156af20511dPharmaRadar360en2026-09-26T13:56:55.000ZPeople don't realise how food safety lapses risk public health: Mundhehttps://www.pharmaradar360.com/article/biohaven-ltd-bhvn-stock-price-news-quote-and-history-fb88cd800d8486a4PharmaRadar360en2026-09-26T13:43:20.000ZBiohaven Ltd. (BHVN) stock price, news, quote and historyhttps://www.pharmaradar360.com/article/fg-plans-wider-role-for-pharmacists-in-nigeria-s-healthcare-system-2ad038d37b1e7ddbPharmaRadar360en2026-09-26T13:30:00.000ZFG Plans Wider Role For Pharmacists In Nigeria’s Healthcare System -https://www.pharmaradar360.com/article/total-equity-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-bse-indra-r-00f908fabf9044daPharmaRadar360en2026-09-26T13:19:57.000ZTotal equity of Indrayani Biotech Ltd. Right 2026-25.06.26 For Shares – BSE:INDRA_REhttps://www.pharmaradar360.com/article/russia-attacks-darnytsia-pharmaceutical-plant-for-second-time-in-a-week-cb5106cc9d0ca398PharmaRadar360en2026-09-26T13:02:00.000ZRussia attacks Darnytsia pharmaceutical plant for second time in a weekhttps://www.pharmaradar360.com/article/tame-the-aging-trial-with-metformin-that-never-enrolled-a-patient-6e5dadaf0968b86dPharmaRadar360en2026-09-26T12:29:30.000ZTAME: The Aging Trial with Metformin That Never Enrolled a Patienthttps://www.pharmaradar360.com/article/darnytsia-pharmaceutical-company-hit-by-aggressor-for-second-time-over-week-a029e621c0dc5c54PharmaRadar360en2026-09-26T12:29:19.000ZDarnytsia pharmaceutical company hit by aggressor for second time over weekhttps://www.pharmaradar360.com/article/astellas-doses-first-patient-in-phase-3-trial-of-setidegrasib-for-kras-g12d-muta-c428c99ab0d4452fPharmaRadar360en2026-09-26T12:13:02.000ZAstellas Doses First Patient in Phase 3 Trial of Setidegrasib for KRAS G12D-Mutated Lung Cancerhttps://www.pharmaradar360.com/article/will-priority-review-change-takeda-stock-s-narrative-fcb5f6d65b62f1d7PharmaRadar360en2026-09-26T11:50:00.000ZWill Priority Review Change Takeda Stock's Narrativehttps://www.pharmaradar360.com/article/is-sellas-life-sciences-group-sls-fully-priced-as-sls009-data-draws-attention-33c46e2f002a8753PharmaRadar360en2026-09-26T11:26:00.000ZIs SELLAS Life Sciences Group (SLS) Fully Priced As SLS009 Data Draws Attention?https://www.pharmaradar360.com/article/pharmaceutical-keynote-speaker-for-events-scott-steinberg-2114dc5da09c0841PharmaRadar360en2026-09-26T11:25:47.000ZPharmaceutical Keynote Speaker for Events | Scott Steinberghttps://www.pharmaradar360.com/article/preity-zinta-s-team-tukaram-mundhe-t-shirt-receives-a-response-from-the-fda-comm-64781058aebeee2fPharmaRadar360en2026-09-26T11:01:00.000ZPreity Zinta’s ‘Team Tukaram Mundhe’ T-shirt receives a response from the FDA Commissioner himself. ‘Havenhttps://www.pharmaradar360.com/article/opinion-why-do-clinical-trials-for-cancer-drugs-take-so-long-5af8d4c7ae806337PharmaRadar360en2026-09-26T11:00:08.000ZOpinion | Why Do Clinical Trials for Cancer Drugs Take So Long?https://www.pharmaradar360.com/article/ai-drug-discovery-on-the-eve-of-full-value-realization-in-modern-pharmaceutical-06757b6282d027abPharmaRadar360en2026-09-26T10:52:25.000ZAI Drug Discovery: On the Eve of Full Value Realization in Modern Pharmaceutical Innovationhttps://www.pharmaradar360.com/article/clinical-data-harmonization-is-the-bottleneck-for-life-sciences-ai-6523456644754b15PharmaRadar360en2026-09-26T10:37:04.000ZClinical data harmonization is the bottleneck for life sciences AIhttps://www.pharmaradar360.com/article/commentary-the-prescription-drug-affordability-board-is-working-it-s-time-to-pre-c716bb20e31d28e8PharmaRadar360en2026-09-26T10:18:42.000ZCommentary: The Prescription Drug Affordability Board is working, it's time to press forward, not backhttps://www.pharmaradar360.com/article/results-are-due-monday-from-a-study-of-two-potential-treatments-for-an-age-relat-87cd3e491349b862PharmaRadar360en2026-09-26T10:05:31.000ZResults are due Monday from a study of two potential treatments for an age-related eye disease.https://www.pharmaradar360.com/article/what-s-next-in-ataxia-pipeline-overview-of-investigational-therapeutics-84047120bac91bc5PharmaRadar360en2026-09-26T10:02:37.000ZWhat's Next in Ataxia: Pipeline Overview of Investigational Therapeuticshttps://www.pharmaradar360.com/article/the-drug-industry-s-care-gap-novo-aims-to-diversify-and-more-94fb54d839beca63PharmaRadar360en2026-09-26T10:00:00.000ZThe drug industry’s care gap; Novo aims to diversify; and morehttps://www.pharmaradar360.com/article/daratumumab-pomalidomide-maintenance-after-salvage-autologous-transplantation-in-c3e01295f5bae9d3PharmaRadar360en2026-09-26T09:34:29.000ZDaratumumab ± pomalidomide maintenance after salvage autologous transplantation in relapsed multiple myeloma: a phase 2 study | Blood Cancer Journalhttps://www.pharmaradar360.com/article/russia-hits-kyiv-pharmaceutical-plant-second-time-in-a-week-f81a10d67ee2ab91PharmaRadar360en2026-09-26T09:31:06.000ZRussia Hits Kyiv Pharmaceutical Plant Second Time in a Weekhttps://www.pharmaradar360.com/article/us-thalidomide-survivors-push-for-federal-recognition-and-compensation-c0a598d4b846436dPharmaRadar360en2026-09-26T09:00:00.000ZUS thalidomide survivors push for federal recognition and compensationhttps://www.pharmaradar360.com/article/russian-forces-strike-darnytsia-pharmaceutical-plant-in-kyiv-again-14945dbed4fb36a5PharmaRadar360en2026-09-26T08:58:00.000ZRussian forces strike Darnytsia pharmaceutical plant in Kyiv againhttps://www.pharmaradar360.com/article/ultragenyx-pharmaceutical-inc-nasdaq-rare-stock-has-consensus-price-target-of-34-cc9516ac59c30051PharmaRadar360en2026-09-26T08:34:28.000ZUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock Has Consensus Price Target of $34.58 According to Analystshttps://www.pharmaradar360.com/article/fda-approves-baricitinib-for-severe-alopecia-areata-in-adolescents-12-b0565e53ceb12441PharmaRadar360en2026-09-26T07:28:44.000ZFDA approves baricitinib for severe alopecia areata in adolescents 12+https://www.pharmaradar360.com/article/eli-002-7p-phase-2-data-selected-for-esmo-2026-oral-presentation-51bca2865302a680PharmaRadar360en2026-09-26T06:43:43.000ZELI-002 7P Phase 2 Data Selected for ESMO 2026 Oral Presentationhttps://www.pharmaradar360.com/article/russia-struck-the-pharmaceutical-company-darnitsa-for-the-second-time-in-four-da-e1a4757d3eb9349fPharmaRadar360en2026-09-26T06:32:53.000ZRussia struck the pharmaceutical company "Darnitsa" for the second time in four dayshttps://www.pharmaradar360.com/article/simply-wearing-a-t-shirt-is-not-enough-fda-chief-tukaram-mundhes-reacts-to-preit-39989874a8f5d9a0PharmaRadar360en2026-09-26T06:05:59.000ZSimply Wearing A T-Shirt Is Not Enough: FDA Chief Tukaram Mundhes REACTS To Preity Zintas Viral Teamhttps://www.pharmaradar360.com/article/total-assets-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-bse-indra-r-0ebd88a86d57b92bPharmaRadar360en2026-09-26T05:34:13.000ZTotal assets of Indrayani Biotech Ltd. Right 2026-25.06.26 For Shares – BSE:INDRA_REhttps://www.pharmaradar360.com/article/fda-launches-inspection-at-kmf-dairies-across-22-districts-afa99d2d8639ec2aPharmaRadar360en2026-09-26T05:27:08.000ZFDA launches inspection at KMF dairies across 22 districtshttps://www.pharmaradar360.com/article/pancreatic-cancer-emerging-breakthroughs-and-clinical-strategies-686d4bc8668cb3c4PharmaRadar360en2026-09-26T04:16:57.000ZPancreatic Cancer: Emerging Breakthroughs and Clinical Strategies